Outcome | Voriconazole | LAmB | ||||
---|---|---|---|---|---|---|
Proportion (%) | Cost (TL) | Proportionate cost (TL)* | Proportion (%) | Cost (TL) | Proportionate cost (TL)* | |
No baseline fungal infection | ||||||
Successful treatment | 24.58 | 11,551 | 2,839 | 29.62 | 19,492 | 5,774 |
Mortality | 7.95 | 11,551 | 919 | 5.92 | 19,492 | 1,155 |
Breakthrough fungal infection | 1.93 | 29,777 | 574 | 4.98 | 31,593 | 1,572 |
Premature discontinuation | 9.88 | 30,179 | 2,982 | 6.64 | 29,784 | 1,976 |
Persistent fever | 52.53 | 30,350 | 15,943 | 51.42 | 30,075 | 15,465 |
Baseline fungal infection | ||||||
Successful treatment | 1.45 | 11,551 | 167 | 0.95 | 25,832 | 245 |
Mortality | 0.00 | 0 | 0 | 0.00 | 0 | 0 |
Persistent baseline fungal infection | 1.69 | 24,400 | 412 | 0.47 | 36,207 | 172 |
Total | 100.00 | -- | 23,835 | 100.00 | -- | 26,358 |